Back to People

Chong Xu, Ph.D.

Partner

About

Chong Xu is a Partner at F-Prime Capital. He focuses primarily on biopharmaceutical and medical technology sectors. He also works closely with the Eight Roads Ventures Asia team to manage portfolio companies and new investment opportunities in China. At F-Prime, Chong has been involved in a number of company formations including as a founding investor of AlphaGen Theraputics, Pediatrix, Skyline Tx, K36 Tx, and RareStone Group. Other companies Chong holds or has held board positions also include OnCusp Tx, Remunix, Shinobi Tx, Sironax, Semma Tx, Adagene, Innovent, etc. Prior to joining F-Prime in 2015, Chong was a management consultant at McKinsey and Company, a hedge fund healthcare equity analyst at Massif Partners and Affirmed Healthcare, and a researcher focusing on developmental neurobiology at Temasek Life Sciences Laboratory in Singapore.

Chong holds a Ph.D. in Cell Biology from University of Virginia and a MBA from Darden School of Business, University of Virginia. He received his B.S. in biology from Zhejiang University, China.

  • Adagene (Nasdaq: ADAG) is an antibody discovery and engineering company with proprietary Smart Antibody Technology, which increases success rates, substantially accelerates time to market, and reduces the costs associated with developing a therapeutic antibody. Learn more at www.adagene.com.

    • Category

      • Therapeutics

    • Status

      • Public

    • Location

      Suzhou, China

    • Year Invested

      2011

    • Team

      Chong Xu, Ph.D.

  • Adcentrx is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease-fighting power of small molecule payloads, Adcentrx strives to develop next-generation targeted therapies for improving patient treatment options. Learn more: https://www.adcentrx.com/

    • Category

      • Therapeutics

    • Status

      • Private

    • Location

      San Diego, CA and Shanghai, China

    • Year Invested

      2023

    • Team

      Chong Xu, Ph.D.

  • AlphaGen Therapeutics is a radiopharmaceutical company focused on the discovery, development and commercialization of innovative targeted radioligand therapies (RLTs). Leveraging its cutting-edge technology platform, the company aims to develop targeted RLTs for patients in China and around the world. Learn more: www.alphagentx.com/

  • Alternative Bio’s mission is to translate the discovery of novel protein synthesis regulatory nodes into first-in-class precision medicines to treat the most challenging cancers. The company’s vision is to establish itself as a global pioneer in this new research space as it advances breakthrough therapies to benefit cancer patients worldwide.

    Learn more at abio-x.com.

    • Category

      • Therapeutics

    • Status

      • Private

    • Location

      Singapore

    • Year Invested

      2022

    • Team

      Chong Xu, Ph.D.

  • b-ONE Ortho Corp. is an emerging orthopedic technology company dedicated to the development of innovative orthopedic healthcare solutions that restore patient mobility and improve surgical outcomes. Every day we are committed to becoming the most credible choice for orthopedic products worldwide.

    Learn more at b1.co.

  • Zhejiang Bang Er Medical Investment Management Co., Ltd. is a leading private medical service provider that operates several private hospitals specializing in orthopedic care and related services in China. Learn more at www.zjbanger.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Zhejiang, China

    • Year Invested

      2015

    • Team

      Chong Xu, Ph.D.

  • Better Life Medical is a fully-integrated hearing aid manufacturer developing and commercializing novel digital programmable hearing aid solutions for the Chinese market. Learn more at www.goblm.com.cn/.

  • BioRegen Biomedical is a fully integrated medical product company based on a proprietary technology platform. BioRegen is developing and commercializing high quality hyaluronic acid (“HA”) based products for the Chinese market. Learn more at www.bioregenmed.com.

    • Category

      • MedTech

    • Status

      • Private

    • Location

      China

    • Year Invested

      2010

    • Team

      Chong Xu, Ph.D.

  • Through the synergies of cross-disciplinary collaboration and technological innovation, EurekaBio has consistently pushed the boundaries of therapy. EurekaBio has brought forth advanced cellular drug production solutions and the EuLV™ lentiviral vector platform. These breakthroughs, including high-titer stable lentiviral vector packaging and producer cell lines, are poised to play a pivotal role in the global commercialization of CGT drugs. Our ultimate aim is to bring tangible benefits to patients worldwide by ushering in a new era of advanced and accessible therapies. Learn more: https://www.eurekabio.com/

  • Eyebright Medical Technology Co., Ltd. (SHA: 688050) is an emerging leader in the ophthalmologic device market in China. Learn more at www.ebmedical.com.

    • Category

      • MedTech

    • Status

      • Public

    • Location

      Beijing, China

    • Year Invested

      2015

    • Team

      Chong Xu, Ph.D.

  • FCB Health is a health insurance and services company that aims to resolve the longstanding financial burden of rising medical expenses in rural China. FCB Health was acquired by Interpublic Group (IPG).

    • Category

      • Health IT/Services

    • Status

      • Acquired

    • Location

      Jiangsu, China

    • Year Invested

      2019

    • Team

      Chong Xu, Ph.D.

  • Gyenno is a digital health company based in Shenzhen, China that is developing a holistic specialty care platform to improve diagnosis, disease management, and clinical research in Parkinson’s Disease and other CNS disorders. Lean more at www.gyenno.com/index-en.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Shenzhen, China

    • Year Invested

      2021

    • Team

      Chong Xu, Ph.D., Connie Li

  • Health Technology is a mobile platform for hospitals that connects patients, optimizes the patient’s hospital visit experience, and streamlines administrator workflow. Learn more at www.gzhc365.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Guangzhou, China

    • Year Invested

      2016

    • Team

      Chong Xu, Ph.D.

  • Innovent Biologics (1801.HK) has built a robust pipeline of innovative and commercially promising monoclonal antibodies and other biologics in the fields of oncology, ophthalmology, autoimmune, and cardiovascular diseases. Learn more at www.innoventbio.com.

  • Insilico specializes in artificial intelligence for drug discovery, biomarker development and aging research. Learn more at www.insilico.com.

    • Category

      • Therapeutics

    • Status

      • Private

    • Location

      Hong Kong

    • Year Invested

      2019

    • Team

      Chong Xu, Ph.D.

  • K36 Therapeutics was established with the mission to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapies. Its vision is to create breakthrough therapies for the unmet medical needs of cancer patients worldwide. Learn more at https://www.k36tx.com/.

  • KnowYourself is a digital health company that is focused on promoting mental wellness in China.

    Learn more at knowyourself.cc.

  • LakeShore Biopharma (NASDAQ:LSB), formerly YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer.

    Learn more at lakeshorebio.com.

    • Category

      • Therapeutics

    • Status

      • Public

    • Location

      Beijing, China

    • Year Invested

      2012

    • Team

      Chong Xu, Ph.D.

  • LenoMed is a company that develops and produces insulin pumps.  Learn more at www.lenomed.com.cn.

    • Category

      • MedTech

    • Status

      • Private

    • Location

      Shanghai, China

    • Year Invested

      2018

    • Team

      Chong Xu, Ph.D.

  • MediTrust Health is a provider of payment services for medical healthcare. The company is dedicated to helping patients solve their own medical payment problems through financial insurance, manage medical expenses more efficiently, and providing value to patients around medical finance, curative effect insurance, and drug benefits, helping patients manage their medical expenses. Learn more at www.meditrusthealth.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Shanghai, China

    • Year Invested

      2017

    • Team

      Chong Xu, Ph.D., Connie Li

  • Nanos Medical develops, manufactures and markets minimally invasive interventional therapy medical devices in the field of ENT, cardiovascular and others. Learn more at www.nanosmedical.com.

    • Category

      • MedTech

    • Status

      • Private

    • Location

      Shanghai, China

    • Year Invested

      2019

    • Team

      Chong Xu, Ph.D.

  • NeuroSmart is an operator of an education and research center focusing on autism. The company helps patients with autism through scientific research and early intervention application, providing families with a comprehensive scientific family intervention program.

    Learn more at neurosmartinc.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Zhejiang, China

    • Year Invested

      2021

    • Team

      Chong Xu, Ph.D., Alex Wong

  • OnCusp Therapeutics, Inc., headquartered in New York City, is a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide. OnCusp was co-founded by Dr. Bing Yuan, Dr. Eric Slosberg, and Dr. Andy Fu, and has built a strong team of accomplished veterans with proven track records in building startup biotechs, leading successful preclinical and clinical programs, and creating value through global partnerships. The company is committed to accelerating the advancement of globally competitive oncology assets for patients. Learn more: https://www.oncusptx.com/

  • Orient Speech Therapy Limited (“OST”) is a Hong-Kong based healthcare services provider that operates a chain of private speech therapy clinics in China. Learn more at www.dfqy.com.

  • Pediatrix Therapeutics is a pharmaceutical company focused on the field of pediatrics by developing and introducing effective and clinically proven children’s medicines to provide Chinese children and families with high-quality and affordable treatment options.

    Learn more at pediatrixtherapeutics.com.

  • RareStone (formerly Citrine Medicine) is a rare disease-focused therapeutics company focused on the Greater China market that was co-founded by Eight Roads Ventures, F-Prime Capital and Vivo Capital. RareStone is dedicated to improving the lives of rare disease patients by making diagnosis and essential treatments available and accessible for those who need them. Learn more at www.rarestonegroup.com.

  • REDPINE is a medical technology company that provides complete solutions for medical business. It focuses on the research and development and production of single-use Class III medical devices, initially endoscopes for urology and gynecology. Learn more at en.gzredpine.com.

  • Semma Therapeutics is a regenerative medicine company founded to develop transformative stem cell-derived therapies to provide a functional cure for patients with diabetes. This company was acquired by Vertex in 2019.

  • Shinobi Therapeutics is a biotechnology company developing a new class of off-the-shelf immune evasive iPSC-derived cell therapies. Based on the research of scientific co-founders Shin Kaneko, M.D., Ph.D., at Kyoto University and Tobias Deuse, M.D., at University of California, San Francisco, Shinobi has created a new allogeneic CD8αβ iPS-T cell platform that demonstrates comprehensive immune evasion from all arms of the immune system. For more information, please visit www.shinobitx.com.

  • Silexon is an emerging AI-empowered technology company which aims to create an open AI platform for strategic collaboration in order to facilitate data-driven life science research and empower drug R&D process, and ultimately provide patients with greater access to innovative drugs for unmet medical needs.

    • Category

      • Therapeutics

    • Status

      • Private

    • Location

      Nanjing, China

    • Year Invested

      2021

    • Team

      Chong Xu, Ph.D.

  • Sironax is a developer of pharmaceuticals for inflammatory and neuro-degenerative diseases. The company researches apoptosis and other cell death pathways to develop quality pharmaceuticals, enabling healthcare professionals to prescribe advanced treatments to their patients.

    Learn more at sironax.com.

  • Skyline Therapeutics (formerly Geneception) is a fully-integrated gene and cell therapy based in Hangzhou and Shanghai, China.  Founded by F-Prime Capital, Eight Roads Ventures China and Lilly Asia Ventures in 2018, Skyline’s mission is to become a preeminent gene and cell therapy company, working to deliver world-class therapeutics for patients in China and globally.

    Learn more at skytx.com.

  • Structure Therapeutics (NASDAQ: GPCR) is a clinical-stage global biopharmaceutical company discovering and developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs.  Learn more at www.structuretx.com.

  • TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven and physics-based high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution. Learn more at www.tandemai.com.

    • Category

      • Therapeutics

    • Status

      • Private

    • Location

      Shanghai, China and New York, NY

    • Year Invested

      2023

    • Team

      Chong Xu, Ph.D.

  • Wanhu provides integrated pharmacy benefit management services in China to better manage drug use and control costs. Learn more at www.wanhuhealth.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      China

    • Year Invested

      2017

    • Team

      Chong Xu, Ph.D.

  • Zeen Health is a health IT company developing prescription digital therapeutics (PDT) for various mental health disorders. Learn more at zeenhealth.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Shenzhen, China

    • Year Invested

      2021

    • Team

      Chong Xu, Ph.D., Alex Wong